SI-BONE, Inc. (SIBN) is a leading medical device company known for pioneering the field of minimally invasive sacroiliac (SI) joint treatment. Founded in 2008, the company is headquartered in Santa Clara, California, with additional offices across the United States and internationally. The company is publicly traded on the NASDAQ under the symbol "SIBN".
The company is primarily focused on the development of innovative and proprietary treatment methods for patients suffering from the debilitating effects of SI Joint disorders. The sacroiliac joint is often a significant source of lower back pain and its diagnosis and treatment have historically been problematic due to the complex nature of the joint and surrounding anatomy. SI-BONE, Inc. addresses this issue by delivering cutting-edge technology and dedicated procedural solutions.
The company's flagship product is the iFuse Implant System®. It is a minimally invasive surgical (MIS) solution that uses a small series of triangular, titanium implants to stabilize and fuse the sacroiliac joint. This differs from the traditional open surgical sacroiliac joint fusion methods that involve significant bone removal and large, less anatomically fitting implants. Since its inception, the iFuse Implant System® has been used in over 45,000 procedures and is backed by a large amount of published clinical evidence demonstrating its effectiveness and safety.
In 2020, SI-BONE, Inc. introduced iFuse Bedrock™, an innovative technology to treat adult patients with degenerative sacroiliitis and sacroiliac joint disruptions. This has further boosted the company’s ability to meet the unfulfilled needs of patients suffering from sacroiliac joint disorders.
Corporate responsibility is also a key pillar in SI-BONE, Inc.’s operations. The company is committed to upholding high ethical standards in its business practices and strives to make a positive impact on society through an emphasis on patient safety, environmental sustainability, and robust corporate governance structures.
Since its foundation, SI-BONE, Inc. has positioned itself at the forefront of the spine industry. The company has continued to innovate and improve treatments for sacroiliac joint disorders, significantly improving the quality of life for thousands of patients worldwide. SI-BONE, Inc. remains committed to maintaining the highest standards of patient care, research, and product innovation.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
SI-BONE, Inc. (SIBN) is a medical devices company specializing in innovative orthopedic solutions with notable potential for investors. Analysts have given the company strong buy ratings, forecasting a 38.58% potential upside with an average target price of $25.00. Despite a negative EPS and return on equity, SI-BONE shows promising revenue growth and strategic reinvestment in R&D, positioning it for long-term growth in the healthcare sector.
SI-BONE (NASDAQ: SIBN) expects a charge of up to $150,000 due to a recall of approximately 3,900 iFuse TORQ implants. The recall was prompted by a packaging defect that posed a potential infection risk, requiring quarantine, repackaging, and re-sterilization. Despite this, the company projects no impact on third-quarter revenue, assuring sufficient inventory for continued supply.
SI-BONE, Inc. director Jeffrey W. Dunn exercised stock options and subsequently sold 20,000 shares of common stock on September 1, 2026, under a pre-arranged 10b5-1 trading plan. The shares were acquired at an exercise price of $4.68 each and sold at a weighted-average price of $18.908 per share. After these transactions, Dunn directly holds 16,057 shares and indirectly holds 81,073 shares through a living trust.
Si-Bone (SIBN) has been identified as a strong momentum stock with a Zacks Rank of #2 (Buy) and a Momentum Style Score of B. The article highlights its recent positive price performance, outperforming both its industry and the S&P 500 over various periods. Additionally, positive earnings estimate revisions further support its promising outlook for investors seeking near-term growth.
SI-BONE's CEO & Director, Laura Francis, recently sold US$279k worth of stock at US$18.66 per share, reducing her total holding by 2.8%. This follows a larger sale earlier in the year of US$1.4m worth of shares at a lower price of US$15.44. While insiders own about 3.6% of the company, the consistent selling without any purchases suggests caution for potential investors.